The first step, click to enter the Alipay app, click to search the medical insurance code;
The second step, click to enter the medical insurance code;
The third step, click to select Agree to the agreement and activate the medical insurance code;
The fourth step is to click Start to complete the application for medical insurance for targeted drugs.
Targeted drugs refer to drugs that target specific mutations or specific biological mechanisms. In recent years, with the development of tumor genomics and protein engineering, targeted drugs have gradually become new treatments. There are currently a number of targeted drugs on the market or in the process of marketing applications. However, due to their high prices, if you want to use these targeted drugs to treat tumors, you must apply through medical insurance.
Before applying for medical insurance for targeted drugs, patients need to consult their doctor to understand whether it is necessary to apply for medical insurance. If you decide to apply for medical insurance, you need to prepare the following materials:
(1) Previous hospitalization records for treatment of the disease (copy with official seal);
(2) Pathology report (examination (Original and copy);
(3) Diagnostic certificate (original and copy);
(4) Genetic test report (original and copy);
p>
(5) Personal ID card and the agent’s ID card (the original will be verified and a copy will be retained);
(6) Personal social security card (the original will be verified and a copy will be retained).
Generally, the review period is 30 days, but for particularly major, complex or difficult applications, it may be extended to 60 days.
Before formally submitting an application, patients should also consult relevant personnel to understand the current national policy requirements for targeted drugs.
The following types of targeted drugs are included in medical insurance:
1. Dacomitinib tablets (Dozerun)
Treatment of cancer: non-small cell Lung cancer
Scope of medical insurance reimbursement: Single drug for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion mutation or exon 21 L858R substitution mutation ) first-line treatment for patients.
2. Ensartinib Hydrochloride Capsules (Bemena)
Treatment of cancer: non-small cell lung cancer
Scope of medical insurance reimbursement: Applicable to patients who have previously received Treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib or are intolerant to crizotinib.
3. Fumetinib Mesylate Tablets (Eversa)
Treatment of cancer: non-small cell lung cancer
Scope of medical insurance reimbursement: use of this product Disease progression during or after previous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment, and the presence of EGFR T790M mutation-positive locally advanced or metastatic non-small cell lung cancer ( Treatment of adult patients with NSCLC).
4. Abeciclib Capsules (Weise)
Treatment of cancer: breast cancer
Scope of medical insurance reimbursement: This product is suitable for hormone receptors (HR) Positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: 1. Use in combination with aromatase inhibitors as initial endocrine therapy in postmenopausal female patients; 2. In combination with fulvestrant For patients with disease progression after previous endocrine therapy.
5. Neratinib maleate tablets (He Li'an)
Treatment of cancer: breast cancer
Scope of medical insurance reimbursement: applicable to human epidermal growth factor receptor Adult patients with HER2-positive early-stage breast cancer receive intensive adjuvant therapy after trastuzumab-containing adjuvant therapy.
6. Eribulin mesylate injection
Treatment of cancer: breast cancer
Scope of medical insurance reimbursement: This product is suitable for patients who have received at least two previous patients with locally advanced or metastatic breast cancer. Previous chemotherapy regimens should have included an anthracycline and a taxane.
Legal basis:
Article 28 of the "Social Insurance Law of the People's Republic of China" complies with the basic medical insurance drug catalog, diagnosis and treatment items, medical service facility standards, and emergency, The medical expenses for rescue shall be paid from the basic medical insurance fund in accordance with national regulations.